22-38129523-C-T
Variant summary
Our verdict is Pathogenic. Variant got 20 ACMG points: 20P and 0B. PS1PM1PM2PP3_StrongPP5_Very_Strong
The ENST00000332509.8(PLA2G6):c.1117G>A(p.Gly373Arg) variant causes a missense change. The variant allele was found at a frequency of 0.00000137 in 1,461,770 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Pathogenicin ClinVar. Synonymous variant affecting the same amino acid position (i.e. G373G) has been classified as Likely benign.
Frequency
Consequence
ENST00000332509.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PLA2G6 | NM_003560.4 | c.1117G>A | p.Gly373Arg | missense_variant | 8/17 | ENST00000332509.8 | NP_003551.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PLA2G6 | ENST00000332509.8 | c.1117G>A | p.Gly373Arg | missense_variant | 8/17 | 1 | NM_003560.4 | ENSP00000333142.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461770Hom.: 0 Cov.: 31 AF XY: 0.00000275 AC XY: 2AN XY: 727198
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Infantile neuroaxonal dystrophy Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | UCLA Clinical Genomics Center, UCLA | Jul 15, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 26, 2018 | This variant has been reported as either homozygous or in combination with another PLA2G6 variant in individuals affected with infantile neuroaxonal dystrophy or late-onset PLA2G6-associated neurodegeneration (PMID: 19138334, 22934738, 25326637) and segregated with this condition in a family (Invitae external communication). ClinVar contains an entry for this variant (Variation ID: 159728). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with arginine at codon 373 of the PLA2G6 protein (p.Gly373Arg). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and arginine. A mouse model generated by a mutagen that randomly induces point mutations throughout the genome has shown that this missense change results in a significant reduction in calcium responses to ATP in astrocytes (PMID: 19893029, 20947703, 22442204). However, the possibility that there are additional mutations in the neighboring genes of PLA2G6 could not be formally excluded. For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 22, 2021 | The c.1117G>A (p.G373R) alteration is located in exon 8 (coding exon 7) of the PLA2G6 gene. This alteration results from a G to A substitution at nucleotide position 1117, causing the glycine (G) at amino acid position 373 to be replaced by an arginine (R). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). A Chinese patient, reported to have the p.G373R and p.K545E alterations, was diagnosed with infantile neuroaxonal dystrophy. The patient was free of symptoms at birth and achieved normal developmental milestones before onset of symptoms at 7 months, which rapidly progressed to a vegetative state by 5 years. Brain MRI imaging showed cerebellar atrophy and neuropathology showed the typical presence of axonal swelling and spheroid bodies (Wu, 2009). Another Chinese patient with late onset PLA2G6-related neurodegeneration was confirmed to be compound heterozygous with this alteration and the p.I689F alteration based on parental testing. Age of onset was at 14 years with gait disturbance followed by mental and behavioral problems after two years and a brain MRI showing cerebellar atrophy and progressive iron accumulation in the globus pallidus and substantia nigra (Zhang, 2013). The p.G373R alteration was in trans with p.S504L in another Chinese patient with PLA2G6-related neurodegeneration. His brother was also affected but had a milder phenotype (Chen, 2018). This amino acid position is highly conserved in available vertebrate species. This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Iron accumulation in brain Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Feb 08, 2013 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at